Cargando…
MiR-192靶向负调控Bim表达诱导肺癌顺铂耐药
BACKGROUND AND OBJECTIVE: Cisplatin is the first-line drug for the chemotherapy of non-small cell lung cancer (NSCLC), but the acquired chemoresistance restricted the effect of its treatment. The aim of this study is to validate the miRNAs related to the Cisplatin resistance in lung cancer and eluci...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000442/ https://www.ncbi.nlm.nih.gov/pubmed/24854555 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.04 |